ARTICLE | Finance
Bain, RTW, Atlas and Lyra back freshly created company with implied $570M valuation
By Paul Bonanos, Director of Biopharma Intelligence
May 17, 2024 5:49 PM UTC
A four-investor syndicate is supplying $400 million to create a start-up that holds most global rights to a portfolio of diabetes and obesity medicines from China-based Hengrui, launching with a valuation of about $570 million.
Bain Capital Life Sciences, RTW Investments, Atlas Venture and Lyra Capital have invested in Hercules CM Newco Inc., according to a regulatory disclosure from Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Shanghai:600276)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652456/hengrui-metabolic-programs-spun-out-into-start-up-with-400m